Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7349189 | 1.00 | ALDH1A1 (0.64) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL6897369 | 0.91 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL6897362 | 0.91 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL22091977 | 0.85 | POLB (0.47) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL7064833 | 0.84 | SDCBP (0.47) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL7064840 | 0.84 | SDCBP (0.47) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL30278688 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL21895831 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL21895832 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL7064130 | 0.83 | ALDH1A1 (0.48) | ALDH1A1POLBKDM4ETP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
| CN-113454058-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound comprising the same, and method for producing the same | 中外制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020122182-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | 中外製薬株式会社 | 2020-06-18 | — | — | WO | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| US-5654294-A | CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646276-A | ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE INHIBITORS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5635502-A | ANALGESIC, HYPOTENSIVE AGENT, DIURETIC, AND USED FOR TREATMENT OF CONGESTIVE HEART FAILURE OR IRRITABLE BOWEL SYNDROME | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-03 | — | — | US | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0669936-A1 | NOVEL MERCAPTOACETYLAMIDE BICYCLIC LACTAM DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMACEUTICALS INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994010193-A1 | NOVEL MERCAPTOACETYLAMIDE BICYCLIC LACTAM DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-4661479-A | ENZYME INHIBITORS | MERCK AND CO., INC. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0061187-B1 | BICYCLIC LACTAMS AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4415496-A | HYPOTENSIVE AGENTS; 5-OXOTHIAZOLO/3,2-A/AZEPINE DERIVATIVES FROM A PHTHALIMIDE | MERCK & CO., INC. (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0061187-A1 | Bicyclic lactams as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | ALDH1A1 4817/4885POLB 4724/4885KDM4E 4113/4885 |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | ALDH1A1 3772/4885POLB 4116/4885KDM4E 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.